Altered	O
Actions	O
of	O
Memantine	O
and	O
NMDA	O
-	O
Induced	O
Currents	O
in	O
a	O
New	O
Grid2	B-GP
-	O
Deleted	O
Mouse	B-OG
Line	O

These	O
authors	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

Memantine	O
is	O
a	O
non	O
-	O
competitive	O
antagonist	O
of	O
the	O
N	B-GP
-	I-GP
methyl	I-GP
-	I-GP
d	I-GP
-	I-GP
aspartate	I-GP
(	I-GP
NMDA	I-GP
)	I-GP
receptor	I-GP
,	O
and	O
is	O
an	O
approved	O
drug	O
for	O
the	O
treatment	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
Alzheimer	B-DS
’	I-DS
s	I-DS
disease	I-DS
.	O

We	O
identified	O
a	O
mouse	B-OG
strain	O
with	O
a	O
naturally	O
occurring	O
mutation	O
and	O
an	O
ataxic	O
phenotype	O
that	O
presents	O
with	O
severe	O
leg	O
cramps	O
.	O

To	O
investigate	O
the	O
phenotypes	O
of	O
these	O
mutant	O
mice	B-OG
,	O
we	O
screened	O
several	O
phenotype	O
-	O
modulating	O
drugs	O
and	O
found	O
that	O
memantine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
disrupted	O
the	O
sense	O
of	O
balance	O
in	O
the	O
mutants	O
.	O

Moreover	O
,	O
the	O
mutant	O
mice	B-OG
showed	O
an	O
attenuated	O
optokinetic	O
response	O
(	O
OKR	O
)	O
and	O
impaired	O
OKR	O
learning	O
,	O
which	O
was	O
also	O
observed	O
in	O
wild	O
-	O
type	O
mice	B-OG
treated	O
with	O
memantine	O
.	O

Microsatellite	O
analyses	O
indicated	O
that	O
the	O
Grid2	B-GP
gene	O
-	O
deletion	O
is	O
responsible	O
for	O
these	O
phenotypes	O
.	O

Patch	O
-	O
clamp	O
analysis	O
showed	O
a	O
relatively	O
small	O
change	O
in	O
NMDA	O
-	O
dependent	O
current	O
in	O
cultured	O
granule	O
cells	O
from	O
Grid2	B-GP
gene	O
-	O
deleted	O
mice	B-OG
,	O
suggesting	O
that	O
GRID2	B-GP
is	O
important	O
for	O
correct	O
NMDA	B-GP
receptor	I-GP
function	O
.	O

In	O
general	O
,	O
NMDA	B-GP
receptors	I-GP
are	O
activated	O
after	O
the	O
activation	O
of	O
non	O
-	O
NMDA	B-GP
receptors	I-GP
,	O
such	O
as	O
AMPA	B-GP
receptors	I-GP
,	O
and	O
AMPA	B-GP
receptor	I-GP
dysregulation	O
also	O
occurs	O
in	O
Grid2	B-GP
mutant	O
mice	B-OG
.	O

Indeed	O
,	O
the	O
AMPA	O
treatment	O
enhanced	O
memantine	O
susceptibility	O
in	O
wild	O
-	O
type	O
mice	B-OG
,	O
which	O
was	O
indicated	O
by	O
balance	O
sense	O
and	O
OKR	O
impairments	O
.	O

The	O
present	O
study	O
explores	O
a	O
new	O
role	O
for	O
GRID2	B-GP
and	O
highlights	O
the	O
adverse	O
effects	O
of	O
memantine	O
in	O
different	O
genetic	O
backgrounds	O
.	O

1	O
.	O

Introduction	O

Memantine	O
(	O
3	O
,	O
5	O
-	O
dimethyl	O
-	O
1	O
-	O
adamantanamine	O
)	O
is	O
an	O
approved	O
drug	O
in	O
the	O
treatment	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
Alzheimer	B-DS
’	I-DS
s	I-DS
disease	I-DS
(	O
AD	B-DS
).	O

Ca2	O
+-	O
mediated	O
excitotoxicity	O
in	O
neurons	O
is	O
one	O
proposed	O
mechanism	O
of	O
AD	B-DS
,	O
and	O
the	O
N	B-GP
-	I-GP
methyl	I-GP
-	I-GP
d	I-GP
-	I-GP
aspartate	I-GP
(	I-GP
NMDA	I-GP
)	I-GP
receptor	I-GP
is	O
one	O
of	O
the	O
major	O
receptor	O
channels	O
responsible	O
for	O
glutamate	O
-	O
induced	O
Ca2	O
+	O
influx	O
.	O

Memantine	O
binds	O
and	O
non	O
-	O
competitively	O
inhibits	O
NMDA	B-GP
receptors	I-GP
,	O
which	O
subsequently	O
protects	O
neurons	O
from	O
glutamate	O
-	O
induced	O
excitotoxicity	O
[	O
1	O
,	O
2	O
].	O

Glutamate	O
is	O
essential	O
for	O
excitatory	O
synaptic	O
transmission	O
mediated	O
by	O
ionotropic	B-GP
glutamate	I-GP
receptors	I-GP
,	O
which	O
include	O
NMDA	B-GP
receptors	I-GP
and	O
non	O
-	O
NMDA	B-GP
receptors	I-GP
,	O
α	O
-	O
amino	O
-	O
3	O
-	O
hydroxy	O
-	O
5	O
-	O
methyl	O
-	O
4	O
-	O
isoxazolepropionic	O
acid	O
(	O
AMPA	O
)	O
and	O
kainate	B-GP
receptors	I-GP
[	O
3	O
].	O

NMDA	B-GP
receptor	I-GP
activation	O
is	O
dependent	O
on	O
the	O
membrane	O
potential	O
that	O
is	O
evoked	O
by	O
non	O
-	O
NMDA	B-GP
receptor	I-GP
function	O
[	O
4	O
].	O

Under	O
pathological	O
conditions	O
,	O
the	O
voltage	O
-	O
dependent	O
regulation	O
of	O
NMDA	B-GP
receptors	I-GP
is	O
believed	O
to	O
be	O
impaired	O
,	O
and	O
memantine	O
is	O
thought	O
to	O
alleviate	O
excitotoxicity	O
by	O
the	O
unregulated	O
NMDA	B-GP
receptor	I-GP
.	O

Unlike	O
memantine	O
,	O
other	O
NMDA	B-GP
receptor	I-GP
antagonists	O
,	O
such	O
as	O
MK	O
-	O
801	O
[	O
5	O
],	O
are	O
considered	O
neurotoxins	O
because	O
they	O
inhibit	O
normal	O
excitotoxic	O
neurotransmission	O
as	O
well	O
as	O
pathological	O
physiological	O
neurotransmission	O
.	O

Although	O
memantine	O
is	O
considered	O
a	O
relatively	O
safe	O
drug	O
,	O
some	O
adverse	O
effects	O
,	O
such	O
as	O
dizziness	O
[	O
6	O
],	O
have	O
been	O
reported	O
.	O

Such	O
adverse	O
effects	O
are	O
likely	O
to	O
result	O
from	O
individual	O
differences	O
among	O
patients	O
,	O
especially	O
in	O
their	O
genetic	O
backgrounds	O
.	O

However	O
,	O
the	O
causes	O
of	O
adverse	O
effects	O
to	O
memantine	O
have	O
not	O
yet	O
been	O
clarified	O
.	O

The	O
glutamate	B-GP
receptor	I-GP
ionotropic	I-GP
delta	I-GP
2	I-GP
(	O
GRID2	B-GP
,	O
also	O
known	O
as	O
GluRδ2	B-GP
)	O
is	O
abundantly	O
expressed	O
in	O
cerebellar	O
Purkinje	O
cells	O
,	O
and	O
shares	O
sequence	O
homology	O
with	O
other	O
glutamate	B-GP
receptors	I-GP
.	O

Despite	O
its	O
name	O
and	O
these	O
homologies	O
,	O
GRID2	B-GP
does	O
not	O
bind	O
glutamate	O
or	O
other	O
glutamate	O
analogs	O
[	O
7	O
,	O
8	O
,	O
9	O
].	O

Mice	B-OG
with	O
an	O
impaired	O
Grid2	B-GP
gene	O
exhibit	O
a	O
broad	O
range	O
of	O
phenotypes	O
,	O
such	O
as	O
cerebellar	B-DS
ataxia	I-DS
,	O
poor	O
motor	O
learning	O
,	O
and	O
memory	O
dysfunction	O
.	O

In	O
addition	O
to	O
the	O
known	O
phenotypes	O
in	O
mice	B-OG
,	O
new	O
phenotypes	O
presumably	O
involving	O
NMDA	B-GP
receptor	I-GP
dysfunction	O
or	O
memantine	O
effects	O
,	O
such	O
as	O
nystagmus	B-DS
(	O
in	O
frogs	B-OG
)	O
[	O
10	O
],	O
oculomotor	B-DS
apraxia	I-DS
(	O
in	O
cats	B-OG
)	O
[	O
11	O
,	O
12	O
],	O
dementia	B-DS
(	O
in	O
humans	B-OG
)	O
[	O
13	O
,	O
14	O
],	O
have	O
been	O
observed	O
in	O
human	B-OG
patients	O
with	O
GRID2	B-GP
gene	O
deletions	O
[	O
15	O
,	O
16	O
,	O
17	O
,	O
18	O
].	O

However	O
,	O
there	O
is	O
not	O
sufficient	O
evidence	O
to	O
ascribe	O
these	O
complex	O
symptoms	O
in	O
human	B-OG
patients	O
to	O
GRID2	B-GP
gene	O
deletions	O
.	O

Here	O
,	O
we	O
report	O
a	O
new	O
deletion	O
in	O
the	O
mouse	B-OG
Grid2	B-GP
gene	O
that	O
is	O
accompanied	O
by	O
ataxia	B-DS
.	O

Administration	O
of	O
memantine	O
led	O
to	O
impaired	O
balance	O
in	O
ataxic	O
mice	B-OG
,	O
and	O
the	O
mutant	O
mice	B-OG
showed	O
deficits	O
in	O
the	O
optokinetic	O
response	O
(	O
OKR	O
)	O
and	O
its	O
learning	O
.	O

These	O
optokinetic	O
impairments	O
were	O
also	O
sensitive	O
to	O
memantine	O
.	O

In	O
addition	O
,	O
only	O
a	O
small	O
population	O
of	O
cultured	O
granule	O
cells	O
isolated	O
from	O
the	O
mutant	O
mice	B-OG
showed	O
memantine	O
-	O
sensitive	O
NMDA	O
-	O
induced	O
currents	O
.	O

These	O
phenomena	O
were	O
mimicked	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	B-OG
following	O
co	O
-	O
treatment	O
with	O
memantine	O
and	O
AMPA	O
.	O

2	O
.	O

Results	O

2	O
.	O
1	O
.	O

The	O
Hereditary	O
Ataxic	O
Mouse	B-OG
is	O
Sensitive	O
to	O
Memantine	O

Two	O
ataxic	O
(	O
male	O
and	O
female	O
)	O
mice	B-OG
appeared	O
spontaneously	O
in	O
the	O
same	O
litter	O
from	O
a	O
mating	O
pair	O
of	O
hetero	O
mice	B-OG
with	O
the	O
knockout	O
(	O
KO	O
)	O
allele	O
for	O
Salt	B-GP
-	I-GP
Inducible	I-GP
Kinase	I-GP
3	I-GP
(	O
Sik3	B-GP
:	O
Sik3tm1Htake	B-GP
/+)	O
[	O
19	O
]	O
on	O
a	O
C57BL	O
/	O
6J	O
(	O
B6	O
)	O
genetic	O
background	O
.	O

The	O
male	O
was	O
Sik3	B-GP
+/−,	O
but	O
the	O
female	O
was	O
Sik3	B-GP
+/+.	O

Because	O
these	O
ataxic	O
mice	B-OG
failed	O
to	O
produce	O
offspring	O
by	O
natural	O
mating	O
,	O
we	O
performed	O
in	O
vitro	O
fertilization	O
(	O
IVF	O
)	O
using	O
these	O
ataxic	O
mice	B-OG
and	O
confirmed	O
the	O
heredity	O
of	O
the	O
phenotype	O
.	O

To	O
expound	O
the	O
mouse	B-OG
population	O
,	O
the	O
original	O
sperm	O
of	O
the	O
ataxic	O
male	O
was	O
also	O
used	O
for	O
other	O
IVF	O
with	O
the	O
oocyte	O
of	O
normal	O
B6	O
female	O
,	O
and	O
offspring	O
with	O
the	O
ataxic	O
phenotype	O
were	O
obtained	O
at	O
the	O
F2	O
generation	O
(	O
numbers	O
of	O
normal	O
male	O
,	O
ataxic	O
male	O
,	O
normal	O
female	O
,	O
and	O
ataxic	O
female	O
were	O
4	O
,	O
1	O
,	O
9	O
,	O
and	O
2	O
,	O
respectively	O
),	O
suggesting	O
a	O
recessively	O
-	O
inherited	O
phenotype	O
.	O

Despite	O
showing	O
normal	O
forelimb	O
movements	O
,	O
the	O
mutant	O
offspring	O
were	O
characterized	O
by	O
a	O
short	O
-	O
stepped	O
gait	O
and	O
frequent	O
falls	O
due	O
to	O
suspected	O
leg	O
cramps	O
(	O
Figure	O
1A	O
).	O

To	O
examine	O
whether	O
the	O
phenotype	O
was	O
caused	O
by	O
a	O
neurogenic	B-DS
disorder	I-DS
,	O
neuropharmacological	O
compounds	O
were	O
tested	O
in	O
the	O
normal	O
and	O
mutant	O
mice	B-OG
.	O

Because	O
anesthesia	O
(	O
1	O
%	O
isoflurane	O
)	O
[	O
20	O
]	O
alleviated	O
leg	O
cramps	O
in	O
the	O
mutant	O
mice	B-OG
,	O
we	O
first	O
selected	O
anticonvulsant	O
drugs	O
including	O
gamma	B-GP
-	I-GP
aminobutyric	I-GP
acid	I-GP
(	I-GP
GABA	I-GP
)	I-GP
receptor	I-GP
activators	O
and	O
NMDA	B-GP
receptor	I-GP
antagonists	O
(	O
Table	O
1	O
).	O

The	O
GABA	B-GP
-	I-GP
A	I-GP
receptor	I-GP
activators	O
felbamate	O
and	O
nitrazepam	O
failed	O
to	O
modulate	O
the	O
phenotypes	O
in	O
the	O
mutant	O
mice	B-OG
.	O

Whereas	O
,	O
memantine	O
(	O
10	O
mg	O
/	O
kg	O
),	O
an	O
NMDA	O
and	O
5HT3	B-GP
receptor	I-GP
antagonist	O
which	O
is	O
also	O
reported	O
to	O
exert	O
agonistic	O
actions	O
for	O
the	O
dopamine	B-GP
D2	I-GP
receptor	I-GP
[	O
21	O
,	O
22	O
],	O
impaired	O
balance	O
in	O
the	O
mutant	O
mice	B-OG
,	O
but	O
not	O
normal	O
mice	B-OG
(	O
Figure	O
1B	O
and	O
Supplementary	O
Movie	O
1	O
).	O

Movement	O
traces	O
of	O
the	O
mice	B-OG
(	O
Figure	O
1C	O
)	O
confirmed	O
that	O
10	O
mg	O
/	O
kg	O
memantine	O
had	O
no	O
significant	O
effect	O
on	O
walking	O
in	O
normal	O
mice	B-OG
.	O

Isolation	O
of	O
ataxic	O
mice	B-OG
with	O
memantine	O
susceptibility	O
.	O

(	O
A	O
)	O
A	O
mouse	B-OG
(	O
6	O
-	O
month	O
-	O
old	O
female	O
)	O
that	O
exhibited	O
an	O
ataxic	O
phenotype	O
with	O
rigid	O
hind	O
limbs	O
.	O

The	O
phenotype	O
became	O
more	O
severe	O
with	O
age	O
;	O
(	O
B	O
)	O
Footprint	O
analyses	O
10	O
min	O
after	O
memantine	O
treatment	O
(	O
10	O
mg	O
/	O
kg	O
,	O
12	O
-	O
week	O
-	O
old	O
male	O
).	O

The	O
soles	O
of	O
the	O
hind	O
limbs	O
were	O
labeled	O
with	O
India	O
ink	O
for	O
a	O
mouse	B-OG
that	O
walked	O
freely	O
on	O
paper	O
.	O

Rollover	O
by	O
the	O
mutant	O
mouse	B-OG
after	O
memantine	O
treatment	O
is	O
shown	O
(	O
lower	O
right	O
);	O
(	O
C	O
)	O
Monitoring	O
mice	B-OG
walking	O
after	O
memantine	O
treatment	O
(	O
10	O
mg	O
/	O
kg	O
,	O
12	O
-	O
week	O
-	O
old	O
male	O
).	O

The	O
position	O
of	O
the	O
mouse	B-OG
’	O
s	O
head	O
was	O
tracked	O
(	O
left	O
),	O
and	O
the	O
walking	O
distance	O
was	O
recorded	O
for	O
5	O
min	O
(	O
right	O
;	O
expressed	O
as	O
the	O
mean	O
and	O
SD	O
;	O
n	O
=	O
6	O
).	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
.	O

Next	O
,	O
we	O
tested	O
other	O
NMDA	B-GP
receptor	I-GP
modulators	O
.	O

Similar	O
to	O
memantine	O
,	O
the	O
NMDA	B-GP
receptor	I-GP
antagonist	O
MK	O
-	O
801	O
(	O
10	O
mg	O
/	O
kg	O
)	O
led	O
to	O
balance	O
disturbances	O
in	O
the	O
mutant	O
mice	B-OG
.	O

However	O
,	O
the	O
normal	O
mice	B-OG
also	O
showed	O
balance	O
disturbances	O
at	O
this	O
dose	O
(	O
Table	O
1	O
).	O

(	O
R	O
)-	O
CPP	O
also	O
produced	O
balance	O
disturbances	O
only	O
in	O
the	O
mutant	O
mice	B-OG
(	O
Supplementary	O
Movie	O
2	O
),	O
whereas	O
ifenprodil	O
,	O
Ro25	O
-	O
6981	O
,	O
or	O
the	O
AMPA	B-GP
receptor	I-GP
antagonist	O
DNQX	O
did	O
not	O
produce	O
balance	O
disturbances	O
in	O
the	O
mutant	O
or	O
normal	O
mice	B-OG
.	O

However	O
,	O
slower	O
movements	O
were	O
observed	O
in	O
mutant	O
mice	B-OG
following	O
administration	O
of	O
DL	O
-	O
AP7	O
.	O

Because	O
serotonin	O
reuptake	O
inhibitors	O
are	O
used	O
to	O
treat	O
vertigo	B-DS
[	O
23	O
],	O
and	O
the	O
5HT3	O
antagonist	O
ondansetron	O
causes	O
headache	O
and	O
dizziness	O
[	O
24	O
],	O
we	O
examined	O
whether	O
ondansetron	O
affected	O
the	O
mutant	O
mice	B-OG
.	O

Both	O
mutant	O
and	O
normal	O
mice	B-OG
showed	O
decreased	O
activity	O
with	O
ondansetron	O
(	O
10	O
mg	O
/	O
kg	O
;	O
Supplementary	O
Movie	O
3	O
),	O
but	O
no	O
effect	O
that	O
was	O
specific	O
to	O
mutant	O
mice	B-OG
was	O
observed	O
.	O

Moreover	O
,	O
enhanced	O
cholinergic	O
signaling	O
following	O
donepezil	O
treatment	O
[	O
21	O
]	O
and	O
activation	O
of	O
dopamine	O
signals	O
by	O
L	O
-	O
Dopa	O
[	O
21	O
,	O
22	O
]	O
had	O
no	O
significant	O
effect	O
on	O
behavior	O
in	O
both	O
normal	O
and	O
mutant	O
mice	B-OG
(	O
Table	O
1	O
).	O

These	O
results	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
the	O
ataxic	O
phenotype	O
,	O
the	O
mutant	O
mice	B-OG
were	O
characterized	O
by	O
enhanced	O
memantine	O
susceptibility	O
,	O
which	O
was	O
probably	O
due	O
to	O
impaired	O
NMDA	B-GP
receptor	I-GP
functions	O
.	O

The	O
inconsistency	O
in	O
the	O
efficacy	O
of	O
NMDA	B-GP
receptor	I-GP
antagonists	O
on	O
balance	O
disturbance	O
might	O
result	O
from	O
differences	O
in	O
NMDA	B-GP
receptor	I-GP
subunit	O
subtype	O
-	O
specificity	O
and	O
/	O
or	O
effective	O
dose	O
among	O
the	O
antagonists	O
;	O
10	O
mg	O
/	O
kg	O
and	O
10	O
–	O
20	O
mg	O
/	O
kg	O
might	O
be	O
the	O
threshold	O
doses	O
to	O
affect	O
balance	O
in	O
the	O
mutant	O
mice	B-OG
for	O
memantine	O
and	O
(	O
R	O
)-	O
CPP	O
,	O
respectively	O
.	O

Pharmacological	O
effectors	O
on	O
mutant	O
mice	B-OG
phenotypes	O
.	O

Chemical	O

Category	O

Dose	O
(	O
mg	O
/	O
kg	O
)	O

Number	O
of	O
Mice	B-OG

Movement	O
of	O
Normal	O
Mice	B-OG

Movement	O
of	O
Mutant	O
Mice	B-OG

Memantine	O

NMDA	B-GP
-	I-GP
R	I-GP
antagonist	O

210	O

22	O

NSNS	O

NSBalance	O
loss	O

MK	O
-	O
801	O

NMDA	B-GP
-	I-GP
R	I-GP
antagonist	O

210	O

23	O

NSBalance	O
loss	O

NSBalance	O
loss	O

DL	O
-	O
AP7	O

NMDA	B-GP
-	I-GP
R	I-GP
antagonist	O

30	O

2	O

NS	O

Slow	O
movement	O

(	O
R	O
)-	O
CPP	O

NMDA	B-GP
-	I-GP
R	I-GP
antagonist	O
(	O
NR2A	B-GP
antagonist	O
)	O

1020	O

42	O

NSNS	O

Balance	O
loss	O
*	O
Balance	O
loss	O

Ro25	O
-	O
6981	O

NMDA	B-GP
-	I-GP
R	I-GP
antagonist	O

210	O

33	O

NSNS	O

NSNS	O

Ifenprodil	O

NMDA	B-GP
-	I-GP
R	I-GP
antagonist	O
(	O
NR2B	B-GP
antagonist	O
)	O

210	O

33	O

NSNS	O

NSNS	O

Felbamate	O

NR2B	B-GP
antagonistGABA	O
-	O
R	O
activator	O

30	O

2	O

NS	O

NS	O

Nitrazepam	O

GABA	B-GP
-	I-GP
R	I-GP
activator	O

30	O

2	O

NS	O

NS	O

Isoflurane	O

GABA	B-GP
-	I-GP
R	I-GP
activator	O

1	O
%	O
in	O
air	O

2	O

Slip	O

Slip	O

DNQX	O

AMPA	O
/	O
Kainatereceptor	O
antagonist	O

210	O

33	O

NSNS	O

NSNS	O

Ondansetron	O

5	O
-	O
HT3	O
antagonist	O

510	O

22	O

NSNot	O
move	O

NSNot	O
move	O

Donepezil	O

acetylcholinesteraseinhibitor	O

10	O

3	O

NS	O

NS	O

l	O
-	O
Dopa	O

Dopamine	O
precursor	O

20	O

3	O

NS	O

NS	O

NS	O
:	O
No	O
significant	O
effect	O
was	O
observed	O
.	O
*:	O
2	O
mice	B-OG
.	O

2	O
.	O
2	O
.	O

Impaired	O
OKR	O
and	O
Learning	O
in	O
the	O
Ataxic	O
Mice	B-OG

Gait	B-DS
disorders	I-DS
are	O
a	O
common	O
pathology	O
in	O
patients	O
with	O
spinocerebellar	O
degeneration	O
,	O
and	O
are	O
sometimes	O
accompanied	O
by	O
vertigo	B-DS
resulting	O
from	O
oculomotor	B-DS
dysfunction	I-DS
[	O
25	O
,	O
26	O
].	O

Memantine	O
also	O
affects	O
oculomotor	O
functions	O
in	O
patients	O
with	O
cerebellar	B-DS
ataxia	I-DS
[	O
27	O
].	O

To	O
examine	O
whether	O
our	O
mutant	O
mice	B-OG
also	O
had	O
oculomotor	B-DS
impairments	I-DS
,	O
we	O
measured	O
the	O
OKR	O
and	O
OKR	O
adaptation	O
,	O
a	O
form	O
of	O
cerebellum	O
-	O
dependent	O
learning	O
[	O
28	O
,	O
29	O
],	O
and	O
used	O
the	O
results	O
from	O
these	O
assays	O
to	O
quantify	O
memantine	O
susceptibility	O
(	O
Supplementary	O
Figure	O
S1	O
).	O

Normal	O
and	O
mutant	O
mice	B-OG
were	O
subjected	O
to	O
the	O
OKR	O
assay	O
and	O
horizontal	O
visual	O
pattern	O
oscillations	O
were	O
given	O
(	O
Figure	O
2A	O
).	O

The	O
normal	O
mice	B-OG
could	O
track	O
the	O
stimulus	O
screen	O
,	O
whereas	O
the	O
mutant	O
mice	B-OG
could	O
not	O
.	O

Memantine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
significantly	O
lowered	O
the	O
overall	O
OKR	O
gain	O
throughout	O
a	O
1	O
h	O
session	O
in	O
normal	O
mice	B-OG
while	O
the	O
OKR	O
in	O
mutant	O
mice	B-OG
was	O
completely	O
abolished	O
(	O
Figure	O
2B	O
).	O

To	O
evaluate	O
OKR	O
adaptation	O
,	O
the	O
mean	O
OKR	O
gain	O
was	O
plotted	O
for	O
each	O
10	O
-	O
min	O
interval	O
(	O
Figure	O
2C	O
).	O

Saline	O
-	O
injected	O
normal	O
mice	B-OG
(	O
control	O
)	O
exhibited	O
a	O
time	O
-	O
dependent	O
increase	O
in	O
the	O
OKR	O
gain	O
,	O
but	O
no	O
gain	O
increase	O
was	O
observed	O
in	O
the	O
mutant	O
or	O
the	O
memantine	O
-	O
treated	O
normal	O
mice	B-OG
.	O

The	O
optokinetic	O
response	O
(	O
OKR	O
)	O
and	O
its	O
susceptibility	O
to	O
memantine	O
.	O

(	O
A	O
)	O
The	O
OKR	O
of	O
normal	O
and	O
mutant	O
mice	B-OG
after	O
intraperitoneal	O
injection	O
of	O
saline	O
(	O
control	O
)	O
or	O
memantine	O
-	O
containing	O
saline	O
(	O
10	O
mg	O
/	O
kg	O
).	O

Measurements	O
commenced	O
10	O
min	O
after	O
injection	O
.	O

Representative	O
OKRs	O
from	O
normal	O
and	O
mutant	O
mice	B-OG
are	O
shown	O
.	O

The	O
relative	O
pupil	O
azimuth	O
is	O
plotted	O
against	O
time	O
.	O

Each	O
trace	O
indicates	O
the	O
average	O
over	O
each	O
10	O
-	O
min	O
period	O
of	O
a	O
1	O
-	O
h	O
measurement	O
session	O
.	O

Screen	O
,	O
movement	O
of	O
the	O
stimulus	O
screen	O
;	O
(	O
B	O
)	O
Overall	O
OKR	O
gain	O
throughout	O
the	O
1	O
-	O
h	O
session	O
with	O
or	O
without	O
memantine	O
.	O

Dots	O
and	O
error	O
bars	O
,	O
mean	O
±	O
SD	O
;	O
n	O
=	O
5	O
for	O
each	O
data	O
point	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
,	O
and	O
****	O
p	O
<	O
0	O
.	O
0001	O
,	O
multivariate	O
ANOVA	O
.	O

The	O
overall	O
OKR	O
gain	O
was	O
calculated	O
by	O
averaging	O
the	O
OKR	O
gains	O
for	O
all	O
10	O
-	O
min	O
periods	O
in	O
a	O
single	O
1	O
-	O
h	O
session	O
(	O
see	O
panel	O
C	O
);	O
(	O
C	O
)	O
Time	O
course	O
of	O
the	O
mean	O
OKR	O
gain	O
for	O
normal	O
(	O
n	O
=	O
5	O
)	O
and	O
mutant	O
(	O
n	O
=	O
5	O
)	O
mice	B-OG
.	O

Each	O
dot	O
indicates	O
the	O
average	O
over	O
a	O
10	O
-	O
min	O
period	O
of	O
a	O
1	O
-	O
h	O
measurement	O
session	O
.	O

Error	O
bars	O
indicate	O
±	O
SD	O
.	O
****	O
p	O
<	O
0	O
.	O
0001	O
vs	O
.	O
the	O
control	O
for	O
time	O
×	O
drug	O
interaction	O
,	O
repeated	O
measures	O
ANOVA	O
.	O

2	O
.	O
3	O
.	O

Microsatellite	O
Analysis	O
in	O
the	O
Ataxic	O
Mice	B-OG

Because	O
the	O
pharmacological	O
analyses	O
were	O
unable	O
to	O
predict	O
the	O
gene	O
responsible	O
for	O
the	O
ataxic	O
phenotype	O
,	O
we	O
performed	O
a	O
microsatellite	O
analysis	O
to	O
identify	O
the	O
gene	O
.	O

Sperm	O
were	O
isolated	O
from	O
an	O
ataxic	O
mouse	B-OG
(	O
N0	O
:	O
C57BL	O
/	O
6J	O
[	O
B6	O
],	O
B6	O
/	O
B6	O
)	O
and	O
used	O
to	O
perform	O
IVF	O
with	O
oocytes	O
from	O
C3H	O
/	O
HeN	O
(	O
C3	O
)	O
mice	B-OG
(	O
normal	O
:	O
C3	O
/	O
C3	O
).	O

Oocytes	O
were	O
prepared	O
from	O
the	O
N1	O
female	O
(	O
B6	O
/	O
C3	O
hetero	O
-	O
mice	B-OG
)	O
and	O
used	O
for	O
a	O
second	O
round	O
of	O
IVF	O
using	O
the	O
original	O
sperm	O
from	O
the	O
N0	O
(	O
B6	O
/	O
B6	O
)	O
ataxic	O
mice	B-OG
,	O
which	O
produced	O
137	O
N2	O
mice	B-OG
(	O
75	O
non	O
-	O
ataxic	O
(	O
the	O
responsible	O
genomic	O
-	O
region	O
should	O
be	O
B6	O
/	O
C3	O
)	O
and	O
62	O
ataxic	O
(	O
the	O
responsible	O
genomic	O
-	O
region	O
should	O
be	O
B6	O
/	O
B6	O
)).	O

Using	O
60	O
microsatellite	O
markers	O
and	O
DNA	O
from	O
eight	O
N2	O
non	O
-	O
ataxic	O
mice	B-OG
,	O
we	O
screened	O
heterogenic	O
-	O
regions	O
composed	O
of	O
both	O
B6	O
and	O
C3	O
chromosomes	O
.	O

We	O
observed	O
that	O
D6Mit149	O
(	O
Chromosome	O
6	O
,	O
48	O
.	O
93	O
cM	O
)	O
was	O
amplified	O
as	O
the	O
heterogenic	O
-	O
type	O
in	O
all	O
eight	O
mice	B-OG
.	O

Next	O
,	O
we	O
analyzed	O
other	O
markers	O
near	O
D6Mit149	O
using	O
DNA	O
from	O
70	O
mice	B-OG
(	O
Figure	O
3A	O
)	O
and	O
narrowed	O
the	O
responsible	O
region	O
to	O
27	O
.	O
3	O
–	O
32	O
.	O
2	O
cM	O
(	O
D6Mit384	O
–	O
D6Mit243	O
),	O
which	O
was	O
also	O
associated	O
with	O
the	O
phenotype	O
of	O
enhanced	O
memantine	O
susceptibility	O
.	O

Identification	O
of	O
the	O
responsible	O
gene	O
.	O

(	O
A	O
)	O
Microsatellite	O
analyses	O
of	O
N2	O
mice	B-OG
.	O

B6	O
,	O
parental	O
allele	O
of	O
the	O
ataxic	O
mouse	B-OG
(	O
C56BL	O
/	O
6J	O
);	O
C3	O
,	O
WT	O
allele	O
of	O
C3H	O
/	O
HeN	O
.	O

N2	O
mice	B-OG
were	O
produced	O
following	O
in	O
vitro	O
fertilization	O
with	O
oocytes	O
from	O
hetero	O
N1	O
(	O
B6	O
/	O
C3	O
)	O
and	O
sperm	O
from	O
the	O
original	O
N0	O
ataxic	O
B6	O
(	O
B6	O
/	O
B6	O
).	O

Markers	O
are	O
described	O
in	O
the	O
Experimental	O
Section	O
.	O

Normal	O
and	O
Mut	O
indicate	O
mice	B-OG
with	O
or	O
without	O
the	O
ataxic	O
phenotype	O
,	O
respectively	O
.	O

The	O
Grid2	B-GP
gene	O
is	O
located	O
29	O
.	O
77	O
cM	O
in	O
chromosome	O
6	O
;	O
(	O
B	O
)	O
The	O
full	O
-	O
length	O
open	O
reading	O
frame	O
ORF	O
of	O
Grid2	B-GP
was	O
amplified	O
from	O
cDNA	O
prepared	O
from	O
the	O
cerebellum	O
of	O
WT	O
and	O
Mut	O
mice	B-OG
;	O
(	O
C	O
)	O
Western	O
blotting	O
for	O
GRID2	B-GP
;	O
(	O
D	O
)	O
A	O
diagram	O
showing	O
break	O
points	O
in	O
the	O
Grid2	B-GP
gene	O
of	O
ataxic	O
mice	B-OG
;	O
(	O
E	O
)	O
Putative	O
protein	O
sequence	O
of	O
GRID2	B-GP
in	O
Grid2Htake	O
/	O
Htake	O
mice	B-OG
is	O
predicted	O
from	O
diagram	O
D	O
and	O
the	O
direct	O
ORF	O
sequence	O
.	O

When	O
we	O
searched	O
for	O
genes	O
that	O
have	O
known	O
associations	O
with	O
ataxic	O
phenotypes	O
,	O
we	O
noticed	O
the	O
Grid2	B-GP
gene	O
at	O
29	O
.	O
77	O
cM	O
[	O
30	O
].	O

To	O
determine	O
whether	O
this	O
gene	O
was	O
responsible	O
for	O
the	O
observed	O
phenotype	O
,	O
the	O
Grid2	B-GP
open	O
reading	O
frame	O
(	O
ORF	O
)	O
was	O
amplified	O
from	O
cDNA	O
prepared	O
from	O
the	O
cerebellum	O
.	O

As	O
shown	O
in	O
Figure	O
3B	O
,	O
the	O
Grid2	B-GP
ORF	O
was	O
approximately	O
1	O
kb	O
shorter	O
in	O
the	O
mutant	O
mice	B-OG
than	O
in	O
the	O
WT	O
mice	B-OG
.	O

In	O
addition	O
,	O
western	O
blotting	O
for	O
GRID2	B-GP
revealed	O
that	O
this	O
protein	O
was	O
absent	O
from	O
the	O
mutant	O
cerebellum	O
(	O
Figure	O
3C	O
).	O

Direct	O
sequencing	O
of	O
the	O
mutant	O
ORF	O
suggested	O
that	O
the	O
region	O
from	O
exon	O
3	O
to	O
exon	O
8	O
might	O
be	O
deleted	O
,	O
which	O
is	O
the	O
longest	O
deletion	O
reported	O
in	O
Grid2	B-GP
mutant	O
mice	B-OG
[	O
31	O
].	O

Chromosome	O
walking	O
(	O
Figure	O
3D	O
)	O
identified	O
the	O
break	O
points	O
110	O
kb	O
upstream	O
from	O
exon	O
3	O
and	O
30	O
kb	O
downstream	O
from	O
exon	O
8	O
,	O
which	O
yielded	O
a	O
truncated	O
GRID2	B-GP
protein	O
similar	O
to	O
that	O
in	O
the	O
Grid2trp	O
/	O
trp	O
,	O
Grid2ho8J	O
/	O
ho8J	O
,	O
and	O
Grid2ho13J	O
/	O
ho13J	O
mutants	O
,	O
but	O
with	O
different	O
flanking	O
peptides	O
(	O
Figure	O
3E	O
).	O

Our	O
laboratory	O
code	O
for	O
mutant	O
mouse	B-OG
lines	O
is	O
Htake	O
,	O
thus	O
the	O
mutant	O
allele	O
is	O
named	O
Grid2Htake	O
.	O

2	O
.	O
4	O
.	O

Altered	O
Sensitivity	O
to	O
NMDA	O
in	O
Cultured	O
Granule	O
Cells	O
of	O
Grid2Htake	O
/	O
Htake	O
Mice	B-OG

GRID2	B-GP
is	O
highly	O
expressed	O
in	O
Purkinje	O
cells	O
,	O
and	O
disruption	O
of	O
GRID2	B-GP
signaling	O
impairs	O
Purkinje	O
cell	O
functions	O
.	O

However	O
,	O
little	O
or	O
no	O
expression	O
of	O
functional	O
NMDA	B-GP
receptors	I-GP
in	O
Purkinje	O
cells	O
of	O
the	O
adult	O
cerebellum	O
has	O
been	O
reported	O
[	O
32	O
].	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
Grid2	B-GP
gene	O
deletion	O
influences	O
cerebellar	O
function	O
by	O
affecting	O
NMDA	B-GP
receptors	I-GP
on	O
granule	O
cells	O
.	O

We	O
examined	O
whether	O
Grid2Htake	O
/	O
Htake	O
mice	B-OG
possessed	O
memantine	O
-	O
sensitive	O
NMDA	B-GP
receptors	I-GP
on	O
cerebellar	O
granule	O
cells	O
,	O
using	O
granule	O
cell	O
-	O
enriched	O
(	O
Purkinje	O
cell	O
-	O
free	O
)	O
primary	O
cultures	O
from	O
P2	O
mice	B-OG
.	O

Quantitative	O
PCR	O
(	O
Figure	O
4A	O
)	O
and	O
western	O
blot	O
analyses	O
(	O
Figure	O
4B	O
)	O
showed	O
that	O
cultured	O
granule	O
cells	O
expressed	O
low	O
,	O
but	O
detectable	O
,	O
levels	O
of	O
Grid2	B-GP
mRNA	O
and	O
GRID2	B-GP
protein	O
.	O

No	O
significant	O
difference	O
in	O
NMDAR1	B-GP
protein	O
level	O
was	O
observed	O
between	O
the	O
cultures	O
derived	O
from	O
normal	O
and	O
Grid2Htake	O
/	O
Htake	O
mice	B-OG
,	O
which	O
was	O
consistent	O
with	O
the	O
result	O
of	O
mRNA	O
(	O
microarray	O
)	O
analyses	O
(	O
Supplementary	O
Table	O
S1	O
).	O

We	O
have	O
to	O
note	O
,	O
however	O
,	O
that	O
no	O
significant	O
interaction	O
between	O
GRID2	B-GP
protein	O
and	O
NMDAR1	B-GP
protein	O
in	O
the	O
total	O
cerebella	O
or	O
cultured	O
granule	O
cell	O
lysate	O
was	O
observed	O
(	O
Supplementary	O
Figure	O
S2	O
),	O
despite	O
the	O
presence	O
of	O
PKC	B-GP
gamma	I-GP
binding	O
to	O
GRID2	B-GP
protein	O
[	O
33	O
].	O

Next	O
,	O
we	O
monitored	O
NMDA	O
-	O
induced	O
currents	O
in	O
cultured	O
granule	O
cells	O
using	O
a	O
whole	O
-	O
cell	O
voltage	O
-	O
clamp	O
technique	O
.	O

At	O
cell	O
densities	O
as	O
low	O
as	O
1	O
.	O
25	O
million	O
cells	O
/	O
mL	O
and	O
a	O
holding	O
potential	O
of	O
−	O
90	O
mV	O
,	O
granule	O
cells	O
from	O
both	O
WT	O
and	O
mutant	O
mice	B-OG
showed	O
no	O
baseline	O
activity	O
(	O
Figure	O
4C	O
).	O

In	O
the	O
absence	O
of	O
memantine	O
(	O
before	O
memantine	O
),	O
NMDA	O
(	O
20	O
µM	O
,	O
2	O
s	O
)	O
induced	O
inward	O
currents	O
that	O
were	O
larger	O
in	O
WT	O
cells	O
than	O
in	O
mutant	O
cells	O
.	O

Furthermore	O
,	O
NMDA	O
-	O
induced	O
currents	O
were	O
reduced	O
in	O
the	O
presence	O
of	O
memantine	O
(	O
after	O
memantine	O
:	O
10	O
µM	O
,	O
30	O
s	O
).	O

However	O
,	O
the	O
magnitude	O
of	O
the	O
memantine	O
-	O
dependent	O
suppression	O
of	O
the	O
NMDA	O
-	O
induced	O
currents	O
varied	O
in	O
the	O
individual	O
cells	O
.	O

To	O
accurately	O
categorize	O
the	O
memantine	O
-	O
sensitive	O
NMDA	O
-	O
induced	O
currents	O
,	O
we	O
divided	O
the	O
cells	O
into	O
two	O
categories	O
based	O
on	O
the	O
ability	O
of	O
memantine	O
to	O
reduce	O
the	O
charge	O
density	O
of	O
NMDA	O
-	O
induced	O
currents	O
by	O
more	O
than	O
75	O
%.	O

According	O
to	O
this	O
classification	O
,	O
51	O
.	O
9	O
%	O
of	O
WT	O
cells	O
and	O
only	O
21	O
.	O
4	O
%	O
of	O
mutant	O
cells	O
were	O
categorized	O
as	O
memantine	O
-	O
sensitive	O
(	O
Figure	O
4D	O
).	O

Moreover	O
,	O
the	O
classification	O
(	O
only	O
open	O
circles	O
)	O
revealed	O
that	O
the	O
values	O
of	O
charge	O
density	O
from	O
the	O
mutant	O
cells	O
fell	O
into	O
a	O
lower	O
range	O
,	O
which	O
produced	O
a	O
significant	O
difference	O
in	O
the	O
variance	O
of	O
the	O
charge	O
density	O
between	O
the	O
WT	O
and	O
mutant	O
groups	O
(	O
Figure	O
4E	O
).	O

These	O
results	O
suggest	O
that	O
mutant	O
mice	B-OG
might	O
possess	O
a	O
poor	O
variation	O
of	O
NMDA	B-GP
receptor	I-GP
with	O
reduced	O
function	O
on	O
their	O
granule	O
cell	O
population	O
.	O

NMDA	O
-	O
responsiveness	O
of	O
cultured	O
cerebellar	O
granule	O
cells	O
.	O

(	O
A	O
)	O
The	O
raw	O
data	O
for	O
quantitative	O
PCR	O
analyses	O
and	O
normalized	O
levels	O
(	O
inset	O
:	O
n	O
=	O
4	O
)	O
of	O
Gird2	O
mRNA	O
are	O
indicated	O
.	O

Total	O
RNA	O
was	O
prepared	O
from	O
total	O
cerebellum	O
,	O
2	O
-	O
week	O
-	O
cultured	O
cerebellar	O
granule	O
cells	O
from	O
neonates	O
(	O
P2	O
),	O
B16F10	O
melanoma	B-DS
cells	O
(	O
non	O
-	O
neuronal	O
negative	O
control	O
);	O
(	O
B	O
)	O
Western	O
blotting	O
was	O
performed	O
using	O
WT	O
and	O
Grid2Htake	O
/	O
Htake	O
(	O
Mut	O
)	O
total	O
cerebella	O
or	O
cultured	O
granule	O
cells	O
.	O

There	O
is	O
no	O
significant	O
difference	O
in	O
NMDAR1	B-GP
protein	O
level	O
;	O
(	O
C	O
)	O
Whole	O
-	O
cell	O
current	O
responses	O
of	O
cultured	O
granule	O
cells	O
derived	O
from	O
WT	O
and	O
Mut	O
mice	B-OG
to	O
local	O
application	O
of	O
NMDA	O
(	O
20	O
µM	O
,	O
2	O
s	O
)	O
before	O
and	O
after	O
treatment	O
with	O
memantine	O
(	O
10	O
µM	O
,	O
30	O
s	O
).	O

Representative	O
currents	O
recorded	O
from	O
single	O
WT	O
and	O
Mut	O
cells	O
.	O

Arrowheads	O
indicate	O
artifacts	O
due	O
to	O
the	O
opening	O
and	O
closure	O
of	O
the	O
electromagnetic	O
valve	O
controlling	O
delivery	O
of	O
NMDA	O
-	O
containing	O
saline	O
;	O
(	O
D	O
)	O
The	O
examined	O
cells	O
were	O
categorized	O
into	O
two	O
groups	O
by	O
memantine	O
susceptibility	O
,	O
and	O
their	O
populations	O
are	O
represented	O
as	O
%	O
fractions	O
.	O

When	O
more	O
than	O
75	O
%	O
of	O
NMDA	O
-	O
induced	O
inward	O
current	O
was	O
suppressed	O
by	O
memantine	O
,	O
the	O
cells	O
were	O
categorized	O
into	O
the	O
memantine	O
-	O
sensitive	O
group	O
(	O
white	O
area	O
).	O

Cells	O
that	O
experienced	O
reduced	O
inward	O
current	O
suppression	O
after	O
memantine	O
treatment	O
,	O
or	O
no	O
significant	O
inward	O
current	O
were	O
categorized	O
into	O
the	O
memantine	O
-	O
insensitive	O
group	O
(	O
black	O
area	O
).	O
*	O
p	O
=	O
0	O
.	O
0178	O
,	O
likelihood	O
ratio	O
test	O
(	O
WT	O
,	O
n	O
=	O
27	O
;	O
Mut	O
,	O
n	O
=	O
28	O
);	O
(	O
E	O
)	O
Distribution	O
of	O
the	O
total	O
charge	O
density	O
of	O
NMDA	O
-	O
induced	O
inward	O
currents	O
.	O

Open	O
circles	O
(	O
white	O
)	O
and	O
closed	O
triangles	O
(	O
black	O
)	O
indicate	O
the	O
data	O
from	O
cells	O
categorized	O
as	O
D	O
.	O

The	O
magnitude	O
of	O
the	O
total	O
data	O
(	O
white	O
and	O
black	O
)	O
was	O
not	O
significantly	O
different	O
between	O
the	O
WT	O
and	O
mutant	O
cells	O
(	O
medians	O
,	O
1	O
.	O
01	O
and	O
0	O
.	O
64	O
pC	O
/	O
pF	O
,	O
respectively	O
).	O

However	O
,	O
in	O
a	O
comparison	O
of	O
the	O
data	O
from	O
the	O
memantine	O
-	O
sensitive	O
cells	O
(	O
white	O
),	O
there	O
was	O
a	O
significant	O
difference	O
in	O
variance	O
between	O
the	O
WT	O
and	O
mutant	O
cells	O
(*	O
p	O
=	O
0	O
.	O
0120	O
,	O
Brown	O
-	O
Forsythe	O
test	O
).	O

2	O
.	O
5	O
.	O

Mice	B-OG
Treated	O
with	O
Memantine	O
and	O
AMPA	O
Were	O
Unable	O
to	O
Walk	O
Smoothly	O

GRID2	B-GP
deficiency	O
results	O
in	O
dysregulation	O
of	O
AMPA	B-GP
receptors	I-GP
[	O
34	O
,	O
35	O
].	O

To	O
examine	O
whether	O
impaired	O
AMPA	B-GP
receptor	I-GP
functions	O
affected	O
memantine	O
susceptibility	O
,	O
mice	B-OG
were	O
treated	O
with	O
memantine	O
simultaneously	O
with	O
the	O
AMPA	B-GP
receptor	I-GP
agonist	O
AMPA	O
or	O
the	O
antagonist	O
DNQX	O
[	O
36	O
],	O
and	O
the	O
movements	O
of	O
these	O
mice	B-OG
were	O
monitored	O
(	O
Figure	O
5A	O
).	O

The	O
mice	B-OG
treated	O
with	O
AMPA	O
(	O
20	O
mg	O
/	O
kg	O
)	O
walked	O
slowly	O
and	O
sometimes	O
crouched	O
on	O
the	O
floor	O
.	O

However	O
,	O
mice	B-OG
treated	O
with	O
both	O
memantine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
AMPA	O
had	O
increased	O
activity	O
and	O
did	O
not	O
stop	O
walking	O
.	O

In	O
addition	O
to	O
these	O
abnormal	O
behaviors	O
,	O
the	O
mice	B-OG
walked	O
with	O
a	O
mild	O
staggering	O
gait	O
and	O
sometimes	O
slipped	O
(	O
roll	O
-	O
over	O
:	O
Figure	O
5B	O
,	O
Supplementary	O
Movie	O
4	O
).	O

These	O
combined	O
effects	O
of	O
memantine	O
on	O
mouse	B-OG
behavior	O
were	O
not	O
observed	O
when	O
memantine	O
was	O
administered	O
with	O
DNQX	O
(	O
10	O
mg	O
/	O
kg	O
),	O
although	O
the	O
mice	B-OG
treated	O
with	O
DNQX	O
were	O
also	O
sometimes	O
crouched	O
.	O

Moreover	O
,	O
in	O
the	O
Grid2Htake	O
/	O
Htake	O
mice	B-OG
,	O
co	O
-	O
treatment	O
with	O
AMPA	O
and	O
a	O
low	O
dose	O
of	O
memantine	O
(	O
5	O
mg	O
/	O
kg	O
)	O
caused	O
more	O
evident	O
balance	O
impairment	O
than	O
memantine	O
treatment	O
alone	O
(	O
Supplementary	O
Figure	O
S3	O
),	O
suggesting	O
that	O
GRID2	B-GP
deficiency	O
may	O
augment	O
the	O
synergistic	O
action	O
of	O
AMPA	O
and	O
memantine	O
.	O

The	O
effect	O
of	O
AMPA	O
co	O
-	O
treatment	O
could	O
not	O
be	O
evaluated	O
with	O
a	O
higher	O
dose	O
of	O
memantine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
because	O
the	O
maximal	O
effect	O
was	O
induced	O
by	O
this	O
dose	O
of	O
memantine	O
.	O

Effect	O
of	O
AMPA	B-GP
receptor	I-GP
modulators	O
on	O
memantine	O
action	O
in	O
WT	O
mice	B-OG
.	O

(	O
A	O
)	O
Monitoring	O
of	O
walking	O
mice	B-OG
(	O
12	O
-	O
week	O
-	O
old	O
WT	O
male	O
,	O
n	O
=	O
6	O
)	O
after	O
memantine	O
treatment	O
(	O
10	O
mg	O
/	O
kg	O
)	O
combined	O
with	O
AMPA	O
(	O
20	O
mg	O
/	O
kg	O
)	O
or	O
the	O
AMPA	B-GP
receptor	I-GP
antagonist	O
DNQX	O
(	O
10	O
mg	O
/	O
kg	O
).	O

Ten	O
minutes	O
after	O
the	O
treatments	O
,	O
the	O
walking	O
distance	O
for	O
5	O
min	O
was	O
expressed	O
as	O
the	O
mean	O
and	O
SD	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
vs	O
.	O
the	O
other	O
conditions	O
(	O
unpaired	O
t	O
-	O
test	O
;	O
p	O
<	O
0	O
.	O
0001	O
for	O
overall	O
differences	O
,	O
one	O
-	O
way	O
ANOVA	O
);	O
(	O
B	O
)	O
Number	O
of	O
rollovers	O
in	O
5	O
min	O
was	O
counted	O
.	O

NO	O
indicates	O
that	O
rollover	O
was	O
not	O
observed	O
.	O
n	O
=	O
6	O
for	O
Control	O
and	O
AMPA	O
+	O
memantine	O
and	O
n	O
=	O
3	O
for	O
the	O
other	O
conditions	O
.	O

The	O
occurrence	O
of	O
rollover	O
was	O
significantly	O
different	O
between	O
AMPA	O
+	O
memantine	O
and	O
the	O
other	O
conditions	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Fisher	O
’	O
s	O
exact	O
test	O
);	O
(	O
C	O
)	O
OKRs	O
measured	O
in	O
female	O
WT	O
mice	B-OG
with	O
sequential	O
injections	O
of	O
the	O
control	O
saline	O
,	O
AMPA	O
(	O
10	O
mg	O
/	O
kg	O
),	O
or	O
DNQX	O
(	O
5	O
mg	O
/	O
kg	O
)	O
and	O
memantine	O
(	O
5	O
mg	O
/	O
kg	O
).	O

A	O
set	O
of	O
traces	O
indicates	O
representative	O
responses	O
of	O
individual	O
mice	B-OG
.	O

Dotted	O
line	O
,	O
the	O
movement	O
of	O
the	O
stimulus	O
screen	O
;	O
(	O
D	O
)	O
Graph	O
shows	O
the	O
mean	O
and	O
±	O
SD	O
of	O
OKR	O
gain	O
(	O
n	O
=	O
3	O
for	O
each	O
condition	O
).	O
p	O
value	O
(	O
without	O
a	O
bracket	O
,	O
one	O
-	O
tailed	O
unpaired	O
t	O
-	O
test	O
;	O
with	O
brackets	O
,	O
paired	O
t	O
-	O
test	O
)	O
is	O
indicated	O
when	O
significance	O
was	O
observed	O
.	O

Finally	O
,	O
the	O
OKR	O
was	O
monitored	O
after	O
co	O
-	O
treatment	O
with	O
memantine	O
and	O
AMPA	O
or	O
DNQX	O
(	O
Figure	O
5C	O
).	O

Mice	B-OG
were	O
first	O
treated	O
with	O
AMPA	O
,	O
DNQX	O
,	O
or	O
saline	O
,	O
and	O
the	O
OKR	O
was	O
subsequently	O
monitored	O
for	O
5	O
min	O
(	O
because	O
some	O
mice	B-OG
closed	O
their	O
eyes	O
after	O
treatment	O
with	O
higher	O
doses	O
,	O
AMPA	O
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
DNQX	O
(	O
5	O
m	O
/	O
kg	O
)	O
were	O
used	O
for	O
OKR	O
measurement	O
).	O

To	O
evaluate	O
synergies	O
between	O
memantine	O
and	O
AMPA	B-GP
receptor	I-GP
modulators	O
,	O
the	O
mice	B-OG
were	O
further	O
treated	O
with	O
a	O
low	O
dose	O
of	O
memantine	O
(	O
5	O
mg	O
/	O
kg	O
),	O
and	O
again	O
subjected	O
to	O
OKR	O
measurements	O
for	O
another	O
5	O
min	O
.	O

AMPA	O
significantly	O
impaired	O
the	O
OKR	O
,	O
and	O
the	O
combined	O
treatment	O
with	O
memantine	O
further	O
impaired	O
the	O
OKR	O
(	O
Figure	O
5D	O
).	O

These	O
effects	O
were	O
not	O
observed	O
in	O
mice	B-OG
co	O
-	O
treated	O
with	O
memantine	O
and	O
DNQX	O
.	O

3	O
.	O

Discussion	O

Here	O
,	O
we	O
report	O
cross	O
-	O
talk	O
between	O
GRID2	B-GP
signaling	O
and	O
memantine	O
in	O
mice	B-OG
,	O
which	O
may	O
,	O
in	O
part	O
,	O
account	O
for	O
the	O
adverse	O
effects	O
of	O
memantine	O
in	O
patients	O
with	O
individual	O
differences	O
in	O
congenital	O
or	O
acquired	O
genetic	O
factors	O
,	O
such	O
as	O
GRID2	B-GP
.	O

Major	O
phenotypes	O
have	O
been	O
identified	O
in	O
GRID2	B-GP
mutant	O
mice	B-OG
,	O
including	O
impaired	O
motor	O
coordination	O
,	O
learning	O
,	O
and	O
memory	O
.	O

GRID2	B-GP
is	O
located	O
on	O
the	O
postsynaptic	O
membrane	O
of	O
Purkinje	O
cells	O
and	O
binds	O
to	O
cerebellin	B-GP
precursor	I-GP
protein	I-GP
1	I-GP
(	O
CBLN1	B-GP
)	O
and	O
neurexin	B-GP
1	I-GP
beta	I-GP
(	O
NRXN1b	B-GP
)	O
[	O
7	O
,	O
8	O
]	O
on	O
the	O
parallel	O
fibers	O
of	O
granule	O
cells	O
[	O
7	O
,	O
37	O
].	O

On	O
the	O
other	O
hand	O
,	O
the	O
memantine	O
target	O
,	O
NMDA	B-GP
receptors	I-GP
,	O
are	O
also	O
expressed	O
on	O
the	O
developing	O
[	O
38	O
]	O
and	O
adult	O
[	O
39	O
]	O
cerebellar	O
granule	O
cells	O
.	O

Furthermore	O
,	O
contrary	O
to	O
the	O
neurotoxic	O
effects	O
of	O
glutamate	O
,	O
NMDA	B-GP
receptors	I-GP
were	O
found	O
to	O
promote	O
the	O
survival	O
of	O
cultured	O
Purkinje	O
[	O
40	O
]	O
and	O
granule	O
cells	O
[	O
41	O
,	O
42	O
].	O

However	O
,	O
double	O
-	O
KO	O
mice	B-OG
with	O
disrupted	O
Nr2A	B-GP
and	O
Nr2C	B-GP
genes	O
(	O
encoding	O
two	O
major	O
NMDA	B-GP
receptor	I-GP
subunits	O
in	O
the	O
adult	O
mice	B-OG
cerebellum	O
)	O
demonstrate	O
a	O
mild	O
impairment	O
in	O
motor	O
coordination	O
,	O
but	O
they	O
do	O
not	O
exhibit	O
an	O
ataxic	O
phenotype	O
[	O
43	O
].	O

This	O
observation	O
suggests	O
that	O
NMDA	B-GP
receptors	I-GP
and	O
GRID2	B-GP
functions	O
may	O
not	O
be	O
directly	O
linked	O
[	O
44	O
].	O

Thus	O
,	O
in	O
the	O
present	O
study	O
,	O
pharmaco	O
-	O
behavioral	O
approaches	O
failed	O
to	O
identify	O
Grid2	B-GP
as	O
a	O
candidate	O
for	O
the	O
cause	O
of	O
the	O
observed	O
phenotypes	O
.	O

Unexpectedly	O
,	O
our	O
efforts	O
resulted	O
in	O
the	O
observation	O
of	O
new	O
phenotypes	O
in	O
our	O
Grid2	B-GP
deficient	O
mice	B-OG
,	O
which	O
appeared	O
as	O
enhanced	O
memantine	O
susceptibility	O
,	O
which	O
was	O
likely	O
mediated	O
by	O
dysfunctional	O
NMDA	B-GP
receptors	I-GP
[	O
1	O
,	O
2	O
,	O
45	O
].	O

OKR	O
measurements	O
in	O
Grid2Htake	O
/	O
Htake	O
mice	B-OG
revealed	O
impaired	O
basal	O
cerebellar	O
functions	O
in	O
eye	O
movement	O
,	O
which	O
was	O
also	O
mimicked	O
by	O
memantine	O
treatment	O
.	O

Dizziness	O
has	O
been	O
reported	O
as	O
a	O
major	O
adverse	O
effect	O
of	O
memantine	O
treatment	O
in	O
humans	B-OG
[	O
6	O
,	O
46	O
].	O

The	O
cerebellar	O
flocculus	O
is	O
thought	O
to	O
be	O
responsible	O
for	O
the	O
early	O
stage	O
formation	O
of	O
OKR	O
adaptation	O
and	O
its	O
memory	O
[	O
47	O
,	O
48	O
].	O

The	O
Grid2	B-GP
gene	O
is	O
located	O
in	O
a	O
hot	O
spot	O
of	O
genomic	O
deletions	O
[	O
31	O
],	O
and	O
a	O
number	O
of	O
mutant	O
lines	O
with	O
defects	O
in	O
this	O
gene	O
have	O
been	O
identified	O
.	O

In	O
addition	O
to	O
naturally	O
occurring	O
mutants	O
,	O
targeted	O
disruption	O
and	O
knock	O
-	O
in	O
mutations	O
of	O
Grid2	B-GP
have	O
been	O
reported	O
[	O
30	O
,	O
49	O
,	O
50	O
].	O

In	O
contrast	O
to	O
these	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
,	O
Grid2Lc	O
(	O
Lurcher	O
)	O
[	O
51	O
]	O
was	O
identified	O
as	O
a	O
spontaneous	O
dominant	O
mutation	O
characterized	O
by	O
cerebellar	B-DS
ataxia	I-DS
and	O
atrophy	O
of	O
Purkinje	O
and	O
granule	O
cells	O
[	O
30	O
].	O

Physiological	O
studies	O
of	O
Grid2Lc	O
/+	O
mice	B-OG
have	O
shown	O
that	O
the	O
Grid2Lc	O
mutation	O
produces	O
constitutive	O
inward	O
Ca2	O
+/	O
Na	O
+	O
currents	O
that	O
induce	O
cell	O
death	O
[	O
52	O
].	O

The	O
importance	O
of	O
the	O
genetic	O
background	O
on	O
Grid2Lc	O
/+	O
mice	B-OG
phenotypes	O
was	O
also	O
reported	O
[	O
47	O
,	O
53	O
].	O

In	O
congenic	O
Grid2Lc	O
/+	O
mice	B-OG
,	O
almost	O
99	O
.	O
99	O
%	O
of	O
those	O
on	O
a	O
C57BL	O
/	O
6	O
genetic	O
background	O
lost	O
Purkinje	O
cells	O
,	O
whereas	O
no	O
Purkinje	O
cell	O
loss	O
was	O
observed	O
in	O
Grid2Lc	O
/+	O
mice	B-OG
on	O
a	O
93	O
%	O
C57BL	O
/	O
6	O
genetic	O
background	O
,	O
indicating	O
that	O
phenotypes	O
in	O
Grid2Lc	O
/+	O
mice	B-OG
are	O
highly	O
dependent	O
on	O
their	O
genetic	O
backgrounds	O
.	O

Interestingly	O
,	O
abnormal	O
eye	O
-	O
movement	O
and	O
impaired	O
motor	O
-	O
coordination	O
were	O
only	O
observed	O
in	O
93	O
%	O
of	O
C57BL	O
/	O
6	O
background	O
-	O
Grid2Lc	O
/+	O
mice	B-OG
possessing	O
Purkinje	O
cells	O
,	O
but	O
not	O
in	O
99	O
.	O
99	O
%	O
of	O
C57BL	O
/	O
6	O
background	O
-	O
Grid2Lc	O
/+	O
mice	B-OG
without	O
Purkinje	O
cells	O
[	O
47	O
],	O
suggesting	O
that	O
gain	O
of	O
GRID2	B-GP
signaling	O
is	O
also	O
a	O
cause	O
of	O
motor	O
deficits	O
in	O
the	O
presence	O
of	O
Purkinje	O
cells	O
.	O

In	O
contrast	O
to	O
Grid2Lc	O
/+	O
mice	B-OG
,	O
we	O
noticed	O
during	O
gene	O
mapping	O
that	O
memantine	O
-	O
induced	O
balance	O
impairment	O
was	O
observed	O
in	O
Grid2Htake	O
/	O
Htake	O
mice	B-OG
irrespective	O
of	O
their	O
genetic	O
backgrounds	O
(	O
mixed	O
B6	O
and	O
C3	O
backgrounds	O
).	O

This	O
is	O
also	O
the	O
case	O
for	O
random	O
eye	O
movements	O
commonly	O
observed	O
in	O
different	O
Grid2	B-GP
-	O
deleted	O
mice	B-OG
with	O
different	O
genetic	O
backgrounds	O
,	O
Grid2	B-GP
-	O
KO	O
in	O
C57BL	O
/	O
6	O
and	O
Grid2ho	O
-	O
15J	O
/	O
15J	O
on	O
a	O
C3HJ	O
background	O
[	O
17	O
],	O
suggested	O
that	O
memantine	O
-	O
induced	O
balance	O
impairment	O
may	O
occur	O
in	O
other	O
Grid2	B-GP
deficient	O
mice	B-OG
irrespective	O
of	O
their	O
genetic	O
backgrounds	O
.	O

How	O
does	O
the	O
Grid2Htake	O
deletion	O
enhance	O
the	O
actions	O
of	O
memantine	O
?	O

GRID2	B-GP
regulates	O
long	O
-	O
term	O
depression	O
(	O
LTD	O
)	O
at	O
synapses	O
between	O
immature	O
parallel	O
fibers	O
and	O
Purkinje	O
cells	O
by	O
inducing	O
AMPA	B-GP
receptor	I-GP
endocytosis	O
[	O
34	O
,	O
35	O
].	O
d	O
-	O
Serine	O
is	O
an	O
endogenous	O
ligand	O
for	O
GRID2	B-GP
and	O
one	O
of	O
the	O
factors	O
that	O
induce	O
LTD	O
[	O
9	O
].	O

Developing	O
mice	B-OG
that	O
express	O
GRID2	B-GP
with	O
a	O
disrupted	O
d	O
-	O
serine	O
binding	O
site	O
show	O
impaired	O
motor	O
coordination	O
and	O
learning	O
,	O
suggesting	O
the	O
importance	O
of	O
LTD	O
for	O
motor	O
regulation	O
.	O

On	O
the	O
other	O
hand	O
,	O
NMDA	B-GP
receptor	I-GP
activation	O
requires	O
the	O
removal	O
of	O
Mg2	O
+	O
block	O
,	O
which	O
occurs	O
when	O
the	O
membrane	O
potential	O
increases	O
through	O
activation	O
of	O
non	O
-	O
NMDA	B-GP
receptors	I-GP
including	O
AMPA	B-GP
receptors	I-GP
[	O
4	O
].	O

Cooperative	O
signal	O
-	O
transmission	O
from	O
cerebellar	O
mossy	O
fiber	O
-	O
granule	O
cells	O
to	O
Purkinje	O
cells	O
mediated	O
by	O
NMDA	O
and	O
AMPA	B-GP
receptors	I-GP
has	O
been	O
shown	O
in	O
both	O
Mg2	O
+	O
block	O
dependent	O
and	O
independent	O
manners	O
[	O
54	O
].	O

We	O
observed	O
that	O
co	O
-	O
treatment	O
with	O
memantine	O
and	O
AMPA	O
impaired	O
gait	O
and	O
OKR	O
in	O
wild	O
type	O
mice	B-OG
,	O
suggesting	O
that	O
dysregulation	O
of	O
AMPA	B-GP
receptor	I-GP
function	O
in	O
Grid2	B-GP
deficient	O
mice	B-OG
may	O
cause	O
the	O
enhanced	O
memantine	O
susceptibility	O
.	O

This	O
may	O
be	O
implicated	O
in	O
the	O
decreased	O
number	O
of	O
memantine	O
-	O
sensitive	O
NMDA	O
-	O
responsible	O
granule	O
cells	O
in	O
Grid2Htake	O
/	O
Htake	O
mice	B-OG
.	O

Whilst	O
mapping	O
the	O
gene	O
responsible	O
for	O
the	O
ataxic	O
phenotype	O
,	O
we	O
observed	O
new	O
phenotypes	O
in	O
Grid2	B-GP
deficient	O
mice	B-OG
,	O
which	O
were	O
latent	O
balance	O
defects	O
,	O
and	O
OKR	O
impairments	O
.	O

These	O
deficits	O
were	O
also	O
mimicked	O
by	O
memantine	O
with	O
AMPA	O
in	O
the	O
impaired	O
WT	O
mice	B-OG
.	O

Because	O
,	O
recently	O
,	O
the	O
wide	O
distributions	O
of	O
Grid2	B-GP
mRNA	O
and	O
GRID2	B-GP
protein	O
were	O
reported	O
in	O
the	O
adult	O
rodent	O
brain	O
[	O
55	O
],	O
the	O
phenotypes	O
in	O
Grid2Htake	O
/	O
Htake	O
mice	B-OG
could	O
be	O
ascribed	O
to	O
not	O
only	O
attenuated	O
NMDA	B-GP
receptor	I-GP
responsiveness	O
in	O
a	O
subset	O
of	O
granule	O
cells	O
but	O
also	O
other	O
cellular	O
mechanisms	O
.	O

When	O
granule	O
cells	O
are	O
collectively	O
activated	O
in	O
vivo	O
,	O
glutamate	O
spilt	O
over	O
from	O
parallel	O
fiber	O
-	O
Purkinje	O
cell	O
synapses	O
stimulate	O
adjacent	O
interneurons	O
(	O
volume	O
transmission	O
),	O
which	O
in	O
turn	O
exert	O
inhibition	O
of	O
Purkinje	O
cells	O
[	O
44	O
,	O
56	O
,	O
57	O
,	O
58	O
]	O
crucial	O
for	O
normal	O
motor	O
coordination	O
[	O
59	O
].	O

The	O
GRID2	B-GP
mutation	O
may	O
reduce	O
NMDA	B-GP
receptor	I-GP
-	O
mediated	O
excitation	O
of	O
granule	O
cells	O
,	O
and	O
this	O
might	O
decrease	O
the	O
volume	O
transmission	O
and	O
Purkinje	O
cell	O
inhibition	O
via	O
interneurons	O
.	O

Moreover	O
,	O
cerebellar	O
interneurons	O
(	O
basket	O
,	O
stellate	O
,	O
and	O
Golgi	O
cells	O
)	O
also	O
express	O
functional	O
NMDA	B-GP
receptors	I-GP
at	O
their	O
presynaptic	O
membrane	O
[	O
44	O
,	O
56	O
,	O
57	O
,	O
58	O
]	O
and	O
these	O
receptors	O
could	O
be	O
affected	O
by	O
the	O
change	O
of	O
GRID2	B-GP
signaling	O
.	O

Taken	O
as	O
a	O
whole	O
,	O
the	O
present	O
study	O
using	O
a	O
naturally	O
occurring	O
Grid2	B-GP
deleted	O
mouse	B-OG
line	O
may	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
NMDA	O
,	O
AMPA	O
,	O
and	O
GRID2	B-GP
receptors	I-GP
.	O

Further	O
studies	O
are	O
required	O
to	O
elucidate	O
the	O
precise	O
mechanisms	O
underlying	O
GRID2	B-GP
signaling	O
.	O

4	O
.	O

Experimental	O
Section	O

4	O
.	O
1	O
.	O

Animals	B-OG

C57BL	O
/	O
6J	O
(	O
B6	O
)	O
and	O
C3H	O
/	O
HeN	O
(	O
C3	O
)	O
from	O
SLC	O
Japan	O
(	O
Shizuoka	O
,	O
JAPAN	O
)	O
were	O
used	O
for	O
the	O
maintenance	O
of	O
the	O
Grid2Htake	O
/	O
Htake	O
mouse	B-OG
line	O
and	O
for	O
IVF	O
for	O
microsatellite	O
analyses	O
,	O
respectively	O
.	O

IVF	O
was	O
performed	O
following	O
a	O
standard	O
method	O
[	O
60	O
]	O
using	O
human	B-OG
tubal	O
fluid	O
medium	O
(	O
Ark	O
Resource	O
,	O
Kumamoto	O
,	O
Japan	O
).	O

The	O
Grid2	B-GP
mutant	O
mice	B-OG
,	O
Grid2Htake	O
/	O
Htake	O
(	O
formal	O
name	O
is	O
Grid2ho	O
-	O
Htake	O
/	O
Nibio	O
),	O
were	O
supplied	O
by	O
the	O
JCRB	O
Laboratory	O
Animal	O
Resource	O
Bank	O
at	O
the	O
National	O
Institute	O
of	O
Biomedical	O
Innovation	O
.	O

The	O
experimental	O
mouse	B-OG
protocols	O
were	O
approved	O
by	O
the	O
Ethics	O
Committee	O
at	O
the	O
National	O
Institute	O
of	O
Biomedical	O
Innovation	O
(	O
assigned	O
No	O
.	O

DS	O
-	O
23	O
-	O
35	O
),	O
and	O
by	O
the	O
University	O
of	O
Toyama	O
’	O
s	O
Committee	O
on	O
Animal	O
Experiments	O
(	O
assigned	O
No	O
.	O
A2012eng	O
-	O
8	O
)	O
for	O
animal	O
welfare	O
.	O

For	O
microarray	O
analyses	O
,	O
cerebella	O
were	O
dissected	O
after	O
anesthesia	O
of	O
mice	B-OG
with	O
isoflurane	O
(	O
WAKO	O
Pure	O
Chemicals	O
,	O
Osaka	O
,	O
JAPAN	O
).	O

The	O
animals	B-OG
were	O
maintained	O
under	O
standard	O
light	O
(	O
08	O
:	O
00	O
–	O
20	O
:	O
00	O
)	O
and	O
temperature	O
conditions	O
(	O
23	O
°	O
C	O
,	O
50	O
%	O
humidity	O
).	O

4	O
.	O
2	O
.	O

Reagents	O

Microsatellite	O
markers	O
were	O
used	O
to	O
identify	O
the	O
chromosomal	O
region	O
responsible	O
for	O
the	O
ataxic	O
phenotype	O
,	O
(	O
D6Mit86	O
,	O
1	O
.	O
18	O
cM	O
;	O
D6Mit351	O
,	O
22	O
.	O
94	O
cM	O
;	O
D6Mit384	O
,	O
27	O
.	O
38	O
cM	O
;	O
D6Mit243	O
,	O
32	O
.	O
2	O
cM	O
7	O
;	O
D6Mit29	O
,	O
37	O
.	O
75	O
cM	O
;	O
D6Mit102	O
.	O

42	O
.	O
11	O
cM	O
;	O
D6Mit149	O
,	O
48	O
.	O
93	O
cM	O
;	O
D6Mit200	O
,	O
89	O
.	O
28	O
cM	O
).	O

To	O
map	O
the	O
end	O
points	O
of	O
the	O
Grid2	B-GP
deletion	O
,	O
we	O
used	O
following	O
primers	O
:	O
mGrid2	B-GP
intron	O
2H	O
F	O
5	O
'-	O
GCT	O
ACT	O
TTG	O
GTA	O
CAA	O
GTG	O
GAC	O
A	O
and	O
mGrid2	B-GP
intron	O
2H	O
R	O
5	O
'-	O
GAC	O
AAG	O
TTG	O
CTC	O
TCT	O
GTA	O
TCT	O
;	O
mGrid2	B-GP
Intron	O
2I	O
F	O
5	O
'-	O
CAT	O
GCT	O
CAC	O
ATC	O
AAA	O
ATA	O
CAT	O
CAA	O
and	O
mGrid2	B-GP
Intron	O
2I	O
R	O
5	O
'-	O
TGT	O
AAT	O
TGA	O
GGAA	O
AAT	O
ACA	O
TAA	O
T	O
.	O

Other	O
primers	O
used	O
in	O
Figure	O
3D	O
were	O
prepared	O
with	O
reference	O
to	O
[	O
31	O
].	O

To	O
identify	O
the	O
Grid2	B-GP
deletion	O
in	O
Grid2Htake	O
/	O
Htake	O
mice	B-OG
,	O
we	O
used	O
the	O
following	O
primers	O
for	O
PCR	O
amplification	O
:	O
mGrid2	B-GP
Intron	O
2HIF	O
5	O
'-	O
TGG	O
ATC	O
CTT	O
CTA	O
CGT	O
GCA	O
AC	O
,	O
mGrid2	B-GP
Intron	O
8YF2	O
5	O
'-	O
GGA	O
CCA	O
CAC	O
TGA	O
GGT	O
TCG	O
AAA	O
GA	O
,	O
and	O
mGrid2	B-GP
Intron	O
8YR	O
5	O
'-	O
ATC	O
TCT	O
TGG	O
CAT	O
GCA	O
TTA	O
GAC	O
.	O

The	O
mutant	O
allele	O
of	O
Grid2Htake	O
produces	O
a	O
PCR	O
band	O
corresponding	O
to	O
a	O
product	O
of	O
approximately	O
600	O
bp	O
,	O
and	O
that	O
for	O
the	O
WT	O
allele	O
is	O
approximately	O
400	O
bp	O
.	O

GRID2	B-GP
antibody	B-GP
was	O
obtained	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
).	O

Antibodies	B-GP
for	O
NMDAR1	B-GP
and	O
tubulin	B-GP
were	O
obtained	O
from	O
Cell	O
Signaling	O
Technology	O
(	O
Boston	O
,	O
MA	O
,	O
USA	O
).	O

Memantine	O
,	O
AMPA	O
,	O
DNQX	O
,	O
MK	O
-	O
801	O
,	O
nitrazepam	O
,	O
donepezil	O
,	O
and	O
ondansetron	O
were	O
purchased	O
from	O
WAKO	O
Pure	O
Chemicals	O
;	O
ifenprodil	O
,	O
Ro25	O
-	O
6981	O
,	O
DL	O
-	O
AP7	O
,	O
felbamate	O
,	O
and	O
loperamide	O
were	O
obtained	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

4	O
.	O
3	O
.	O

mRNA	O
Analyses	O

Total	O
RNA	O
was	O
prepared	O
from	O
the	O
cerebellar	O
hemispheres	O
of	O
12	O
-	O
week	O
-	O
old	O
mice	B-OG
(	O
male	O
and	O
female	O
)	O
using	O
the	O
EZ1	O
-	O
RNA	O
purification	O
kit	O
(	O
Qiagen	O
,	O
Venlo	O
Park	O
,	O
The	O
Netherlands	O
).	O

For	O
microarray	O
analyses	O
,	O
GeneChip	O
Mouse	B-OG
Genome	O
430A	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
was	O
used	O
,	O
and	O
differences	O
in	O
transcript	O
levels	O
were	O
calculated	O
with	O
Partek	O
(	O
Partek	O
Inc	O
.,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

The	O
original	O
data	O
files	O
(	O
CEL	O
-	O
files	O
)	O
were	O
deposited	O
in	O
the	O
Gene	O
Expression	O
Omnibus	O
(	O
GEO	O
)	O
repository	O
and	O
assigned	O
the	O
GEO	O
accession	O
numbers	O
:	O
GSM1334015	O
,	O
GSM1334016	O
,	O
and	O
GSM1334017	O
for	O
normal	O
mice	B-OG
,	O
and	O
GSM1334018	O
,	O
GSM1334019	O
,	O
and	O
GSM1334020	O
for	O
mutant	O
mice	B-OG
.	O

PCR	O
primers	O
for	O
real	O
-	O
time	O
PCR	O
were	O
as	O
follows	O
:	O
mGrid2	B-GP
F	O
,	O
5	O
'-	O
AAC	O
ACG	O
CTA	O
CAT	O
GGA	O
CTA	O
CTC	O
-	O
3	O
'	O
and	O
mGrid2	B-GP
R	O
,	O
5	O
'-	O
GAA	O
GCA	O
CTG	O
TGC	O
CAG	O
CAA	O
TG	O
-	O
3	O
';	O
mGapdh	B-GP
F	O
,	O
5	O
'-	O
ACT	O
CAC	O
GGC	O
AAA	O
TTC	O
AAC	O
GG	O
-	O
3	O
'	O
and	O
mGapdh	B-GP
R	O
,	O
5	O
'-	O
GAC	O
TCC	O
ACG	O
ACA	O
TAC	O
TGA	O
GC	O
-	O
3	O
'.	O

To	O
amplify	O
the	O
Grid2	B-GP
ORF	O
,	O
primers	O
are	O
mGrid2	B-GP
F2	O
(	O
5ATG	O
):	O
5	O
'-	O
ATG	O
GAA	O
GTT	O
TTC	O
CCC	O
TTG	O
CTC	O
TTG	O
T	O
and	O
mGrid2	B-GP
R	O
(	O
3Stop	O
):	O
5	O
'-	O
TCA	O
TAT	O
GGA	O
CGT	O
GCC	O
TCG	O
GTC	O
GGG	O
GTC	O
A	O
were	O
used	O
.	O

4	O
.	O
4	O
.	O

Measurements	O
of	O
Walking	O
Distance	O
and	O
the	O
OKR	O

Male	O
mice	B-OG
(	O
12	O
–	O
14	O
weeks	O
old	O
)	O
were	O
placed	O
in	O
a	O
rectangular	O
box	O
(	O
25	O
cm	O
×	O
40	O
cm	O
),	O
and	O
their	O
head	O
position	O
was	O
tracked	O
for	O
5	O
min	O
using	O
ANY	O
-	O
maze	O
software	O
(	O
Brain	O
Science	O
Idea	O
,	O
Osaka	O
,	O
Japan	O
).	O

Each	O
mouse	B-OG
was	O
monitored	O
three	O
times	O
,	O
and	O
the	O
longest	O
distance	O
recorded	O
was	O
used	O
in	O
the	O
data	O
analysis	O
.	O

The	O
OKR	O
was	O
measured	O
in	O
adult	O
mice	B-OG
using	O
previously	O
described	O
methods	O
[	O
28	O
],	O
which	O
are	O
depicted	O
in	O
Supplementary	O
Figure	O
S1	O
.	O

Briefly	O
,	O
the	O
mice	B-OG
were	O
anesthetized	O
with	O
isoflurane	O
(	O
2	O
%)	O
and	O
a	O
stainless	O
steel	O
screw	O
was	O
glued	O
to	O
the	O
skull	O
.	O

The	O
mice	B-OG
were	O
then	O
habituated	O
to	O
the	O
experimental	O
conditions	O
for	O
2	O
days	O
before	O
the	O
measurement	O
.	O

Ten	O
minutes	O
before	O
the	O
measurement	O
were	O
made	O
,	O
mice	B-OG
were	O
administered	O
a	O
saline	O
(	O
8	O
mL	O
/	O
kg	O
)	O
injection	O
with	O
or	O
without	O
memantine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
intraperitoneally	O
.	O

The	O
mouse	B-OG
was	O
then	O
mounted	O
on	O
a	O
stereotaxic	O
apparatus	O
and	O
exposed	O
to	O
continuous	O
sinusoidal	O
horizontal	O
oscillations	O
(	O
17	O
°,	O
0	O
.	O
25	O
Hz	O
)	O
of	O
a	O
cylindrical	O
checkerboard	O
-	O
patterned	O
screen	O
(	O
diameter	O
,	O
65	O
cm	O
;	O
single	O
square	O
,	O
1	O
.	O
8	O
×	O
1	O
.	O
8	O
cm	O
;	O
brightness	O
,	O
~	O
30	O
lx	O
).	O

Right	O
eye	O
movement	O
was	O
captured	O
at	O
30	O
Hz	O
with	O
an	O
infrared	O
camera	O
.	O

For	O
each	O
image	O
frame	O
,	O
we	O
used	O
a	O
machine	O
vision	O
system	O
to	O
estimate	O
the	O
pupil	O
azimuth	O
from	O
the	O
location	O
of	O
the	O
pupil	O
center	O
.	O

The	O
OKR	O
was	O
expressed	O
on	O
a	O
time	O
plot	O
of	O
the	O
relative	O
pupil	O
azimuth	O
for	O
each	O
round	O
of	O
screen	O
oscillation	O
,	O
with	O
the	O
pupil	O
azimuth	O
at	O
the	O
beginning	O
of	O
backward	O
eye	O
movement	O
set	O
to	O
0	O
°.	O

An	O
OKR	O
gain	O
was	O
defined	O
as	O
the	O
ratio	O
of	O
the	O
maximal	O
relative	O
pupil	O
azimuth	O
change	O
to	O
that	O
of	O
the	O
screen	O
(	O
17	O
°).	O

4	O
.	O
5	O
.	O

Cell	O
Culture	O
and	O
Electrophysiology	O

Granule	O
cell	O
-	O
enriched	O
cultures	O
were	O
prepared	O
as	O
previously	O
described	O
[	O
61	O
].	O

Briefly	O
,	O
2	O
-	O
day	O
-	O
old	O
(	O
P2	O
)	O
mutant	O
or	O
WT	O
mice	B-OG
were	O
anesthetized	O
by	O
cooling	O
and	O
then	O
sacrificed	O
by	O
decapitation	O
.	O

The	O
cerebella	O
were	O
dissociated	O
with	O
trypsin	B-GP
,	O
plated	O
on	O
poly	O
-	O
l	O
-	O
ornithine	O
-	O
coated	O
plastic	O
dishes	O
(	O
Becton	O
Dickinson	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
,	O
USA	O
)	O
at	O
1	O
.	O
25	O
million	O
cells	O
/	O
mL	O
,	O
and	O
maintained	O
in	O
low	O
-	O
serum	O
,	O
nutrient	O
-	O
supplemented	O
Dulbecco	O
’	O
s	O
Modified	O
Eagle	O
Medium	O
/	O
F	O
-	O
12	O
(	O
Life	O
Technologies	O
;	O
5	O
%	O
CO2	O
,	O
37	O
°	O
C	O
)	O
for	O
12	O
days	O
.	O

Ruptured	O
-	O
patch	O
whole	O
-	O
cell	O
recordings	O
were	O
performed	O
on	O
cultured	O
granule	O
cells	O
.	O

The	O
pipette	O
solution	O
contained	O
134	O
mM	O
potassium	O
d	O
-	O
gluconic	O
acid	O
,	O
7	O
.	O
6	O
mM	O
KCl	O
,	O
9	O
mM	O
KOH	O
,	O
10	O
mM	O
NaCl	O
,	O
1	O
.	O
2	O
mM	O
MgCl2	O
,	O
4	O
mM	O
ATP	O
magnesium	O
salt	O
,	O
10	O
mM	O
HEPES	O
,	O
and	O
0	O
.	O
5	O
mM	O
EGTA	O
(	O
pH	O
7	O
.	O
3	O
).	O

The	O
culture	O
dish	O
was	O
perfused	O
at	O
a	O
rate	O
of	O
1	O
.	O
4	O
mL	O
/	O
min	O
with	O
145	O
mM	O
NaCl	O
,	O
5	O
mM	O
KCl	O
,	O
2	O
mM	O
CaCl2	O
,	O
10	O
mM	O
HEPES	O
,	O
10	O
mM	O
d	O
-	O
glucose	O
,	O
and	O
10	O
µM	O
glycine	O
(	O
pH	O
7	O
.	O
4	O
).	O

Current	O
signals	O
were	O
recorded	O
using	O
an	O
EPC	O
-	O
8	O
amplifier	O
(	O
holding	O
potential	O
,	O
−	O
90	O
mV	O
;	O
cut	O
-	O
off	O
frequency	O
,	O
5	O
kHz	O
;	O
sampling	O
rate	O
,	O
20	O
kHz	O
;	O
HEKA	O
,	O
Lambrecht	O
/	O
Pfalz	O
,	O
Germany	O
)	O
controlled	O
by	O
Patchmaster	O
software	O
(	O
version	O
,	O
2	O
.	O
35	O
;	O
HEKA	O
).	O

The	O
command	O
potentials	O
were	O
corrected	O
for	O
a	O
liquid	O
junction	O
potential	O
between	O
the	O
pipette	O
and	O
bath	O
solutions	O
.	O

Electronic	O
capacitance	O
cancellation	O
and	O
series	O
resistance	O
compensation	O
were	O
not	O
used	O
.	O

The	O
series	O
resistance	O
(	O
33	O
.	O
2	O
±	O
5	O
.	O
1	O
MΩ	O
,	O
n	O
=	O
55	O
)	O
and	O
membrane	O
capacitance	O
were	O
estimated	O
from	O
the	O
amplitude	O
and	O
time	O
constant	O
of	O
the	O
capacitive	O
current	O
evoked	O
by	O
a	O
10	O
mV	O
voltage	O
jump	O
.	O

The	O
bath	O
solution	O
containing	O
20	O
µM	O
NMDA	O
or	O
10	O
µM	O
memantine	O
was	O
locally	O
applied	O
to	O
the	O
cell	O
through	O
a	O
theta	O
tube	O
under	O
the	O
control	O
of	O
gravity	O
and	O
electromagnetic	O
valves	O
(	O
VM8	O
,	O
ALA	O
Scientific	O
Instruments	O
,	O
Farmingdale	O
,	O
NY	O
,	O
USA	O
).	O

The	O
magnitude	O
of	O
an	O
NMDA	O
-	O
induced	O
current	O
was	O
quantified	O
as	O
the	O
inward	O
current	O
charge	O
over	O
a	O
2	O
s	O
NMDA	O
application	O
normalized	O
to	O
the	O
membrane	O
capacitance	O
(	O
charge	O
density	O
).	O

The	O
background	O
charge	O
was	O
estimated	O
from	O
a	O
0	O
.	O
5	O
s	O
pre	O
-	O
application	O
period	O
and	O
subtracted	O
from	O
the	O
charge	O
density	O
.	O

4	O
.	O
6	O
.	O

Statistical	O
Analyses	O

Data	O
from	O
each	O
group	O
were	O
characterized	O
by	O
the	O
mean	O
±	O
SD	O
,	O
unless	O
otherwise	O
stated	O
.	O

Data	O
from	O
biochemical	O
assays	O
were	O
examined	O
with	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
unpaired	O
two	O
-	O
tailed	O
t	O
-	O
tests	O
to	O
detect	O
statistically	O
significant	O
differences	O
.	O

All	O
the	O
statistical	O
examinations	O
were	O
performed	O
using	O
JMP	O
software	O
(	O
versions	O
9	O
.	O
0	O
.	O
2	O
and	O
10	O
.	O
0	O
.	O
1	O
,	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
).	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

